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Abstract
Background. The serum- and glucocorticoid-regulated
kinase (SGK1) gene is an important mediator of
aldosterone action, regulating the expression of the
renal epithelial Naþ channel. In renal failure, blood
pressure (BP) is markedly salt-dependent and increases
with decreasing renal function. Mutations of the SGK1
gene affecting phosphorylation could be responsible
for salt-mediated increases in BP and hypertension-
related progression to end-stage renal disease (ESRD).
Methods. The SGK1 gene was analysed for mutations
in the exons 4, 5, 8 and 10–12, because of potential
phosphorylation sites, in 591 subjects, including 311
ESRD patients (either dialysis or transplanted). In
addition, an intron 6 single-nucleotide polymorphism
(SNP) described previously was also investigated in
this study. Genotyping was performed either by using
a strategy based on single strand conformation
polymorphism analysis of polymerase chain reaction
(PCR) products and subsequent direct sequencing of
identiﬁed gel shift variants or by using high throughput
50 nuclease allelic discrimination assay.
Results. Two SNPs in coding regions of SGK1
potentially inﬂuencing the phosphorylation of Sgk1
were identiﬁed. Both SNPs were synonymous. The
prevalence of the ﬁrst variant, a previously reported
SNP at codon 240 in exon 8, did not differ between
ESRD patients (16.3%) and controls (15.7%). There
was no association between the SNP in exon 8 and
either BP within the control population or progression
of renal disease in the ESRD population. The second
SNP at codon 398 in exon 12 was identiﬁed in one
patient only. Intron 6 and exon 8 SNPs were in strong
linkage disequilibrium, but did not show any associa-
tion with either BP or renal diseases.
Conclusions. Based on statistical analysis homozygos-
ity for nonconservative mutations in the coding region
of the SGK1 gene is estimated at <1/300 000 when
a white Caucasian population is considered, arguing
against an important role of mutations of this coding
region in hypertension and hypertension-associated
progression of renal disease.
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Introduction
The epithelial sodium (Naþ) channel (ENaC) located in
the apical membrane of renal aldosterone-responsive
epithelia, plays an essential role in controlling the Naþ
balance of extracellular ﬂuids and hence blood pressure
(BP) [1,2]. The regulation of ENaC involves a variety
of hormonal signals such as aldosterone, vasopressin
and insulin [3]. Among regulatory proteins found
in recent years the ubiquitin-protein ligase Nedd4-2
negatively controls ENaC cell surface expression, and
the serum glucocorticoid-inducible kinase 1 (Sgk1) acts
as an aldosterone- and insulin-dependent positive
regulator of ENaC density at the plasma membrane [4].
Sgk1 was identiﬁed in 1993 as an immediate early
gene whose mRNA levels increase dramatically within
30min when cells are exposed to serum or glucocorti-
coids, or both [5]. The inactive protein Sgk1 is activated
by phosphorylation in response to several agonists
through a signalling cascade that includes PI3K and the
protein kinases PDK1 and PDK2 [6,7]. Using in vitro
mutagenesis to substitute serine for asparagine at
codon 422 of SGK1, Park et al. [7] showed that Sgk1
becomes fully active under basal conditions. Since
Sgk1 plays an important role in activating ion
channels, this kinase is crucial in regulating processes
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such as cell survival, neuronal excitability and renal
Naþ excretion [8]. Therefore, the SGK1 gene could be
a candidate for abnormal BP regulation and possibly
hypertension. Recently, Busjahn et al. [9] showed a
signiﬁcant association of the SGK1 gene locus to
diastolic BP in twins. There was an association between
two single-nucleotide polymorphisms (SNPs) in exon 8
and intron 6 and BP [9]. In patients with renal disease
BP increases with decreasing glomerular ﬁltration
rate, regardless of the primary cause of the renal
disease [10]. Hypertension in renal failure shows a
marked salt-dependency and is one of the important
contributors for the progressive increase in BP asso-
ciated with the loss of renal function [11]. Therefore,
a genetically determined predisposition to renal
sodium retention could aggravate the sodium reten-
tion observed in renal failure and play an important
role in patients suffering from end-stage renal
disease (ESRD). The aim of the present genetic
association study was to assess whether mutations
of SGK1 affecting phosphorylation sites of the gene
product can be identiﬁed in unselected patients
with hypertension and patients with ESRD. We also
analysed whether the reported association of exon 8
and intron 6 with BP in normotensive twins [9]
is predictive of hypertension or renal failure in
unrelated subjects.
Subjects and methods
Study subjects were 311 patients with ESRD from our
Division of Nephrology and Hypertension (University
Hospital of Berne, Switzerland) and 280 control subjects
without renal disease as described previously [12]. Ethnicity
was homogeneous, with 88% subjects of Swiss German,
9% Mediterranean and 2% Asian origin. Of the control
subjects, 167 were healthy normotensive individuals and
113 had hypertension. Deﬁnitions, characteristics and demo-
graphic data of control subjects and ESRD patients were
described previously [13].
Genotyping
Mutation detection in SGK1was performed in all 591 subjects
using polymerase chain reaction (PCR) to amplify exon 4
(phosphorylation at serine 78), 5 (putative ATP binding site),
8 (phosphorylation by PDK1), 10 (interaction of Sgk1 with
NEDD4-2), 11 (phosphorylation by PKA) and 12 (phosphor-
ylation by PDK2) [6,14–16]. Primers and cycle conditions
are described in Table 1. In addition, intron 6 was ampliﬁed
as described below [9]. The reactions were performed with a
concentration of 1PCR buffer in a ﬁnal volume of 25ml,
with 1.5–4.5mM MgCl2, 1.5U AmpliTaq-Gold-Polymerase
(PE Biosystem, Foster City, CA, USA), 0.2–0.3mM of each
dNTP and 0.4mM of each primer. DNA was used in a
concentration of 100 ng and ampliﬁed with a thermocycler
PCR system 9700 (GeneAmp by Applied Biosystem). PCR
products were analysed using single strand conformational
polymorphism (SSCP) using an established method [12].
Sequence changes were detected by band shift on the gel.
Variants were puriﬁed using QIA-quick PCR puriﬁcation
columns (Qiagen, Chatsworth, CA, USA) according to the
supplier and sequenced byMicrosynth (Balgach, Switzerland)
on an ABI 373A automated sequencer using the same primers
as for PCR. Obtained sequences were compared with SGK1
gene sequence (GenBank gi 18563240).
Genotyping for intron 6 SNP was performed by allelic
discrimination using 50 nuclease assay. The target-speciﬁc
primers and TaqMan MGB probes were sense 50-GGCCA
CTTCCTGCAGTTGT-30, antisense 50-TGCAGGAGACA
GAACAAAGTCATTC-30. As a reporter at the 50 end of
the TaqMan MGB probe, FAM was used for wild-type T
allele (50-FAM-ATTAAATTCATTTGCAACCC-30) and
VIC was used for variant C allele (50-VIC-ATTAAATT
CATTCGCAACCC-30). PCR was performed with a reaction
volume of 25 ml including 12.5ml of TaqMan 2Universal
PCR Master Mix (Applied Biosystems), 0.6 ml of assay mix
and 5 ml of genomic DNA at a concentration of 1–10 ng/ml.
The PCR cycling conditions were: one cycle at 50C for 2 min,
followed by one cycle at 95C for 10min, and 40 cycles at
95C for 15 s and 60C for 1 min. Allelic discrimination was
carried out by measuring ﬂuorescence intensity at the
endpoint by an ABI PRISM Sequence Detection System
7000 (Applied Biosystems). The results of the measurement
Table 1. Primers and conditions used in this study
Exon Primers Cyclesa Annealing
temperature (C)a
MgCl2
(mM)
4 Sense 50-GTC TTC CTT TGA AGC AAT GGT ATT-30 32 63 4.5
Antisense 50-AAG AGG ACA TGA AGG AAG TGT ACC-30
5 Sense 50-ATG TCC TCT TTT GTA TTC TCC CTG-30 32 58 4.5
Antisense 50-GAT TAT TCA AGG AGT GTC TAC CGC-30
8 Sense 50-TGT GCA ACT ACT TTT CTA TTC ACT TTT-30 38 54 4.5
Antisense 50-TGT GCA ACT ACT TTT CTA TTC ACT TTT-30
10 Sense 50-GCC ATA TGA AAC TTC CAA TTA AGT C-30 34 60 1.5
Antisense 50-AGA CAG GTG CAT TCA ATA AGG G-30
11 Sense 50-CTT ATT GAA TGC ACC TGT CTA AA-30 32 62 4.5
Antisense 50-TGA ATT AAA AAT GCC CTT TGG-30
12 Sense 50-CTT GAC AAG AGT GTT TTT CCC TTC-30 36 58 3.5
Antisense 50-ATA AAA TCC TTT AAA ACC AAG CCC-30
aDenaturation at 94C for 30 s, annealing for 30 s and extension at 72C for 1min.
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were analysed using SDS software (Applied Biosystems) and
the genotype was determined.
Ampliﬁcation of exon 8 failed in one subject and
ampliﬁcation of intron 6 was not successful in ﬁve subjects.
Thus, the numbers in Tables 3 and 4 do not add up to
the expected 591 as predicted by the number of subjects
investigated.
Statistical analysis
Differences between means were assessed by the unpaired
t-test or ANOVA. For categorical variables the 2 2
contingency tables by the 2-test was used. The expected
‘disease’ frequency for the target population was calculated
according to the Hardy–Weinberg equation and an estimate
of the probability that, with a given prevalence, mutations
are not detected was obtained by the Armitage equation:
Z¼ (N.p 0.5)/[N.p.(1 p)]2, where p¼ assumed preva-
lence, n¼ number of alleles, N.p.¼ expected number of
mutations, as previously described [12].
Results
A total of two synonymous SNPs in coding regions
of SGK1 potentially inﬂuencing the phosphorylation
of Sgk1 were identiﬁed (Table 2). The ﬁrst SNP was
found in exon 8 and is identical with a previously
reported SNP [9]. The frequency of this C!T
transition at codon 240 in the different study groups
is shown in Table 2. The overall prevalence of this
SNP in exon 8 of the SGK1 gene was 15.9%, the fre-
quency of the wild-type allele was 0.91 and the
frequency of the mutated allele was 0.09.
The expected frequency of the SGK1 exon 8 geno-
type, under the assumption of the Hardy–Weinberg
equilibrium, did not differ from observed frequencies
in ESRD patients and control subjects (Table 2). This
genetic polymorphism was also analysed for its relation
to the rate of progression of renal disease in ESRD
patients and to BP or the presence or absence of
hypertension in the control population. Progression of
renal disease in the ESRD population as a whole was
not inﬂuenced by the SGK1 polymorphism in exon 8
(Table 3). There was no link between the SNP in exon 8
with either systolic or diastolic BP or the presence
or absence of hypertension (2¼ 0.346, P¼ 0.556)
within the control population with normal renal
function (Table 3). The intron 6 and exon 8 SNPs
were in strong linkage disequilibrium, as shown in
Table 4. We grouped both the ESRD and control
population according to the two SNPs into subjects
with exon 8 CT/CCþ intron 6 TT/CT, exon 8 CT/CCþ
intron 6 CC, and exon 8 TTþ intron 6 CC genotypes
as previously described [9]. This association analysis
did not show any signiﬁcant or suggestive association
of the SGK1 gene locus to systolic and diastolic BP
in the control population without ESRD, either with
normal or increased BP (Table 5).
The effect of genotype was analysed in relation to
the aetiology of renal disease in the ESRD population.
Association analysis was performed separately for
patients with glomerulonephritis (N¼ 92), interstitial
nephritis (N¼ 46), polycystic kidney disease (N¼ 39),
diabetes mellitus (N¼ 30), pyelonephritis/vesico-
ureteral reﬂux (N¼ 29), nephroangiosclerosis (N¼ 17)
and other or unknown aetiologies (N¼ 42). This
analysis did not reveal any signiﬁcant outcome on the
prevalence of a given underlying disorder (data not
shown). In particular, the incidence of hypertensive
nephroangiosclerosis was not different among the
described biallelic groups.
The second SNP in the coding region was found
in exon 12 and was identiﬁed in one patient only.
Again, this SNP represented a synonymous muta-
tion, with a T!C mutation at codon 398. There
were no mutations of SNP in exons 4, 5, 10 and 11
detectable in any of the 591 screened patients. We
expected to ﬁnd the polymorphism in exon 10, which
has been described in the SNP database (AS 296
C!T, non-synonymous, reference #rs 1057934),
but none of the 591 screened subjects tested posi-
tive for it. There were a few additional intronic
variants identiﬁed as band shift in the SSCP. One
was a G!A substitution at nucleotide 35 in intron
10 in one subject, another was a G!A substitution
at nucleotide 40 in intron 10, which was found in
two subjects.
Table 2. Identiﬁed mutations in the coding and non-coding regions of the SGK1 gene in control subjects and patients with ESRD
All ESRD Controls
Dialysis Transplanted Hypertension Healthy
N 591 96 215 113 167
Exon 4 – – – – –
Exon 5 – – – – –
Exon 8 C!T Asp240/Asp
Heterozygous 81 (13.7%) 12 (12.5%) 31 (14.4%) 15 (13.0%) 23 (13.4%)
Homozygous 14 (2.4%) 1 (1%) 7 (3.2%) 1 (0.9%) 5 (3.0%)
Exon 10 – – – – –
Exon 11 – – – – –
Exon 12 T!C Ile398/Ile 1 – 1 – –
Intron 6 T!C
Heterozygous 182 (30.8%) 28 (29.2%) 65 (30.2%) 36 (31.8%) 52 (31.1%)
Homozygous 33 (5.6%) 4 (4.2%) 17 (7.9%) 4 (3.5%) 8 (4.8%)
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Discussion
We have analysed the SGK1 gene for association
with ESRD in comparison with normal healthy con-
trols and essential hypertensive patients. SGK1 is a
logical candidate gene because of its role in maintaining
Naþ homeostasis. Because a salt-sensitive BP increase
occurs frequently in patients with chronic renal fail-
ure, contributing to their high prevalence of hyperten-
sion, an increased activity of Sgk1 could result in even
greater Naþ retention and plasma volume expan-
sion. Although two different SNPs in the coding
region of the SGK1 gene were identiﬁed, they were
both synonymous, thus not altering the amino acid
sequence. Therefore, our data argue against an impor-
tant role of nonconservative mutations of the SGK1
gene in a white ESRD population.
Allele frequencies for the SGK1 genotype in exon 8
did not differ signiﬁcantly between control subjects
and ESRD patients or between patients with hyperten-
sion and ESRD; moreover, the same polymorphism
did not show any signiﬁcant effect on the rate of
progression to renal failure. The same applies for the
intron 6/exon 8 SNPs combination, which showed a
similar degree of linkage disequilibrium as previously
reported [9], but had no reproducible effect on BP in
subjects without renal failure. These linked SNPs were
also not associated with a particular cause of renal
disease in ESRD patients. These observations indicate
that these polymorphisms do not have a signiﬁcant
effect on BP in unrelated subjects without renal dis-
eases, do not account for the occurrence of renal
diseases per se and are not a determinant of progressive
renal failure.
In the last decade great progress has been made in
human genetics with the identiﬁcation of an enormous
number of SNPs. However, the impact of these genetic
polymorphisms on the understanding of polygenic
multifactorial cardiovascular diseases like hypertension
has yielded contrasting results [17]. Recently, Busjahn
et al. [9] analysed two SNPs within the SGK1 gene
in monozygotic (126 pairs) and dizygotic (70 pairs)
normotensive twin subjects and parents of dizygotic
twins and found signiﬁcant association of the SGK1
gene locus to diastolic (P<0.0002) and systolic
(P<0.04) BP. These authors concluded that the
SGK1 gene is relevant to BP regulation and probably
to hypertension in man. The relevance of these new
SNPs for the whole hypertensive population, however,
is unclear. In fact the author did not test these two
polymorphisms in hypertensive populations or sub-
groups of hypertensive patients. In our control popu-
lation we could not ﬁnd any association of the SGK1
polymorphic marker in intron 6/exon 8 and BP in
normotensive or hypertensive patients. In the twin
study an association between intron 6 and exon 8 SNPs
and BP in an independent conﬁrmation sample of
260 subjects was described [9]. However, this effect
only applied for 5% of subjects with the exon 8
CT/CC and intron 6 CC polymorphism compared to
94% carriers of the exon 8 CT/CC and intron 6
TT/CT alleles. Genotype distribution was comparable
in our population with 541 (92.7%) subjects having
the intron 6 TT/CT and exon 8 CT/CC genotype and
31 (5.2%) with the intron 6 CC and exon 8 CT/CC
genotype. This distribution was similar for the patients
with or without renal failure. In the control population
with the more prevalent genotype, BP values tended
to be higher in normotensive but lower in hypertensive
subjects, suggesting that these ﬁndings do not support
the observation from the twin study. This view is also
Table 5. BP in subjects with normal renal function according to the
combined exon 8/intron 6 SNP
Phenotype Exon 8 CT/CC Exon 8 CT/CC Exon 8 TT
Intron 6 TT/CT Intron 6 CC Intron 6 CC
N 541 (92.7%) 31 (5.2%) 2 (0.3%)
ESRD 280 (90.0%) 21 (6.7%) 0
Control
population
Normotensive 155 (92.8%) 6 (3.6%) 2 (1.2%)
Hypertensive 106 (93.8%) 4 (3.5%) 0
Systolic BP
(mmHg)
Normotensive 128±16 119±13 127±3
Hypertensive 156±22 167±14
Diastolic BP
(mmHg)
Normotensive 78±8 76±9 77±3
Hypertensive 89±14 99±6
Table 3. Genotype–phenotype analysis of the Asp240Asp variant
in exon 8 of the SGK1 gene in control subjects and patients with
ESRD
Genotype P-value
CC CT TT
Control group (N) 235 38 6
BP (mmHg)
Systolic 140±23 137±21 139±27 0.78
Diastolic 82±13 82±10 79±6 0.89
ESRD 260 43 8
Age at ESRD (years) 47±17 41±17 43±15 0.13
Time to ESRD (years) 11±9 9±8 12±4 0.47
Transplanted subgroup (N) 177 31 7
Age at transplantation
(years)
43±12 41±12 49±15 0.28
P-values are by ANOVA.
Table 4. Linkage disequilibrium between the two SGK1 poly-
morphisms in intron 6 and exon 8
Intron 6
TT TC CC
Exon 8 CC 348 (59.3%) 123 (21.0%) 20 (3.4%)
CT 20 (3.4%) 50 (8.5%) 11 (1.9%)
TT 3 (0.5%) 9 (1.5%) 2 (0.3%)
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supported by experiments using transgenic animals.
Wulff et al. [18] showed with the Sgk1 knockout mouse,
that the phenotype is far less dramatic than the one
observed in the ENaC knockout [19] and the miner-
alocorticoid knockout mice [20]. This suggests that
Sgk1 participates in, but does not fully account for
the mineralocorticoid regulation of ENaC. The iso-
forms Sgk2 and Sgk3 might be able to compensate
for the loss, suggesting that loss of function muta-
tions of the SGK1 gene have no inﬂuence on the
phenotype. Mutations with a gain of function could
still lead to hypertension because of the positive
regulation of ENaC density at the plasma membrane
[4]. However, in our population no mutations with
possible gain of function in the selected gene regions
were identiﬁed.
The lack of association between the SNPs in SGK1
and BP in our population could be due to the relatively
small sample size, although this did not differ from the
conﬁrmation sample described in the former study [9]
and illustrates the problems in determining genetic
inﬂuences in complex traits.
The problem of genetic association studies is not
just to test a given polymorphism in a case–control
study, or in familial design, but also to determine the
relevance of the regulatory transcriptional activity of
the candidate gene with the appropriate assessment
of all the confounding factors. The function of Sgk1
is not limited to regulation of renal ENaC activity, but
is also relevant for other processes since it is expressed
in all human tissues, including pancreas, liver, heart,
lung, skeletal muscle, placenta, kidney and brain [21].
Therefore, it seems unlikely that a functionally relevant
mutation in such a ubiquitous gene would affect BP
regulation only, without showing additional features
of functional signiﬁcance.
The lack of detection of nonconservative mutations
in our population could be due to the small sample
size analysed. Nevertheless, according to the Armitage
equation and for a probability <5% of missing any
signiﬁcant mutation causing an altered Sgk1 kinase
with a total of 1182 alleles analysed, the estimated
prevalence of mutated alleles would be 0.2%. There-
fore, the sample size of this population is too small
to detect signiﬁcant mutations in the SGK1 gene
for an estimated prevalence of 0.15% or less. Thus,
the expected ‘disease’ frequency of homozygous
SGK1 mutants for the target population, calculated
according to the Hardy–Weinberg equation, would be
<1/300 000, considering the frequency of a recessive
allele of <1/550.
The ﬁndings of the present study argue against
an important role of coding regions of Sgk1 in BP
regulation and hypertension and in the hypertension-
related progression of renal diseases. The rate of
nonsynonymous, nonconservative coding SNPs of the
SGK1 altering the amino acid sequence and therefore
generating a kinase with altered activity in this popu-
lation is low. It seems more likely that abnormal
regulation of the SGK1 gene expression, rather than
nonconservative mutations in the coding region of the
gene itself, may play a role in mediating the effects
of Sgk1 in vivo. Homozygosity for nonsynonymous,
nonconservative mutations in the coding region of
the SGK1 gene of exons 4, 5, 8 and 10–12 is <1/300 000
when a white Caucasian population is considered,
arguing against an important role of mutations of
this coding region in hypertension and hypertension-
associated progression of renal disease. Polymorphisms
in regulatory regions may be more important than
variations in coding regions for multifactorial diseases.
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